Company Information
Company Profile
Cash Flow Statement
Profit & Loss
Financial Position
Financial Ratio
Industry 制造业
Company Introduction 成都圣诺生物科技股份有限公司成立于2001年7月，位于成都市大邑县，注册资金5800万元，下属全资子公司有成都圣诺生物制药有限公司。公司从最初的注册资金100万，到目前资产总额达2.5亿，实现了又好又快的发展。拥有成都市级“成都多肽药物工程技术研究中心”，我们0缺陷通过美国FDA认证，现已成为国内一流的专业化多肽类药物和产品开发、技术转让、技术服务和规模化生产、出口的多肽药物产业园区。 公司参与了国家十一五重大新药创制项目《肽化学修饰及工业化规模制备关键技术研究》，承担的国家科技型中小企业技术创新基金无偿资助项目《新型抗心衰药物奈西立肽》已进入临床研究阶段，2010年获得四川省经委的新兴产业专项资金支持，进行多肽药物的产业化成果转化研究，上述项目均已完成了项目建设内容。己具备50多个国内外已上市多肽药物和产品规模化生产关键技术，单批产量均可达kg级;拥有硫环肽规模化生产技术、碳环肽规模化生产技术、复杂多肽技术、多肽快速合成技术等国际领先技术；申请了23项发明专利；已获得5项发明专利授权，凭借其过硬的多肽合成和修饰关键技术，已成为国内多肽行业的领跑者。 公司创始人文永均先生是国内上市第一个多肽药物海南中和的胸腺五肽（和日）和单品种销售收入过5亿的胸腺肽α1的原创人及其稳定多肽药物研发及生产团队的领头者。公司注重学研结合，与川大、兰大、吉大、军科院、中科院有机所、省药检所等科研院校组成了紧密产学研战略合作伙伴关系；为成都地奥、浙江海正、哈药、海南中和等成功实现了多个一类多肽新药的产业化转化。 公司与国外药物多肽同行业合作密切，在印度合作一家多肽生产企业，并对印度工厂的员工进行培训和生产指导，所使用技术均为本公司自有技术；与国际知名多肽技术研究单位保持联系和交流，从多角度、深层次研究生物技术药物的结构、功能，为进一步应用于实际积累科学数据，奠定扎实基础。
Main Business 为国内外医药企业的多肽类创新药研发提供药学研究、定制生产服务，自主研发、生产和销售在国内外具有较大市场容量及较强竞争力的多肽类仿制药原料药和制剂产品以及多肽药物生产技术转让服务。此外，公司还从事小分子化学药物左西孟旦制剂代加工及左西孟旦原料药生产、出口业务。
Legal Representative 文永均
Top Executives
董事长：文永均
董事：宋亚飞,王晓莉,文发胜,余啸海,伍利
独立董事：徐正松,唐英凯,刘霞
Top 5 Shareholder
Shareholder name Nature Holding Date
四川赛诺投资有限公司流通A股37.50%30/09/2024
乐普（北京）医疗器械股份有限公司流通A股5.50%30/09/2024
成都圣诺企业管理中心（有限合伙）流通A股2.97%30/09/2024
中国工商银行股份有限公司－融通健康产业灵活配置混合型证券投资基金流通A股2.68%30/09/2024
中国建设银行股份有限公司－富国精准医疗灵活配置混合型证券投资基金流通A股1.79%30/09/2024
Company Secretary 余啸海
Solicitors 北京海润天睿律师事务所
Auditors 天健会计师事务所（特殊普通合伙）
Tel No 028-88203615
Fax No 028-88203668
Website www.snbiopharm.com
Email snkj@snbiopharm.com
Company Address
Register: 四川省成都市大邑县晋原镇工业大道一段（工业集中发展区内）
Office: 四川省成都市大邑县大安路98号
Listing Date 03/06/2021
Shares Capital
Shares Capital: 112,418,556
Total A Share: 112,418,556
Listed A Share: 112,418,556
Non-tradable A Share: 0
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.630
DPS(RMB)* ¥ 0.200
NBV Per Share(RMB)* ¥ 7.857
Market Capitalization(RMB) 3.114B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.